Annexon Overview
Valuation check: ANNX's ROE is -108.93%, below the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow-108.93%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Annexon (ANNX) currently reports a ROE of -108.93%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Annexon's ROE history and peer comparisons.
Annexon's ROE of -108.93% is lower than the Healthcare sector average of 22.01%. That is roughly 594.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Annexon's current -108.93% should be judged against Healthcare norms (sector average: 22.01%) and against ANNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -108.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Annexon, and consider following ANNX for alerts when major investors trade the stock.
Annexon is classified in the Healthcare sector. On ROE, it currently shows -108.93% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ANNX with unrelated industries.
